Showing 141-150 of 868 results for "".
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
SCALE 2024: Listen as Dr. Joel Cohen Interviews Dr. John H. Joseph on Clinical Trials for Injectables
https://practicaldermatology.com/error/404/John H. Joseph, MD, joins Joel Cohen, MD, to discuss his work on clinical trials for neuromodulators and filler products at Music City SCALE.Physician Spotlight: Bruce H. Thiers, MD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-bruce-h-thiers-md-faad/23407/Physician Spotlight: Anna L. Chien, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-anna-l-chien-md/23488/Lex Icon: Lexington's Randy Waldman Speaks the Language of Successful Site Planning with Joel L. Cohen
https://practicaldermatology.com/topics/practice-management/lex-icon-lexington-s-randy-waldman-speaks-the-language-of-successful-site-planning-with-joel-l-cohen--ovevisoh/18901/How do you plan a brand new, state-of-the art surgical and clinical space that's accessible yet feels exclusive? Should you rent or buy? How do you balance your time? S. Randolph Waldman, MD answers these questions and more from series host Joel L. Cohen, MD in this edition of Best Practices.AK Therapy: Real-life Approaches to Combinations on Scientifically Speaking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-therapy-real-life-approaches-to-combinations-on-scientifically-speaking/19913/From serial PDT to novel combinations, specialists describe how they treat AKs in real-world settings. Scientifically Speaking host Joel L. Cohen, MD reviews cases from Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD.Scientifically Speaking: Optimized Approaches to AK Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-optimized-approaches-to-ak-management/19912/What's new in AK therapy? From a new, first-in-class molecule to updated approaches with long-standing treatments, the management of actinic keratosis continues to evolve. Scientifically Speaking host Joel L. Cohen, MD speaks with Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD about theGold's Standards: Nashville's Laser Guru on Best Practices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/gold-s-standards-nashville-s-laser-guru-on-best-practices/18867/When a third of your practice is dedicated to energy-based devices, it's important to find the best solutions for your patient flow. In this edition of Best Practices, Joel L. Cohen, MD talks to Michael H. Gold, MD about his approach to adoption and promotion of energy-based devices. Dr. Gold discusDermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.